Stocks are on a roll. We have been in a bull market for over a year. Major indexes haven't lost their momentum since 2024 started. However, some stocks aren't keeping pace.

That's the case with biotech giant Bristol Myers Squibb (NYSE: BMY). The drugmaker has seen its shares drop by 22% over the past year. Some might view this situation as an opportunity to buy Bristol Myers' stock on the dip, but it's not worth the trouble unless the company can bounce back.

Let's find out whether there are better days ahead for the business.

Continue reading

Source Fool.com